Generally, the onset of action of Thiotepa fegestatin injection is 22 to 48 hours after injection, but the exact onset of action may vary due to individual differences. Thiotepa fegestatin injection is indicated for the reduction of the incidence of infections manifested by febrile neutropenia in adult patients with non-myeloid malignancies receiving myelosuppressive anticancer drugs that are prone to cause febrile neutropenia. Generally speaking most patients take effect within 22 to 48 hours of dosing, the exact time varies from person to person. Side effects such as fatigue and fever, head discomfort, nausea and vomiting, loss of appetite, and muscle, joint, or generalized pain are possible with Thiopental Fegastine Injection. This drug is contraindicated in people who are allergic to this or other polyethylene glycol recombinant human granulocyte bacterial factor, recombinant human granulocyte stimulating factor, other agents expressed against Escherichia coli, as well as in people with severe hepatic, renal, cardiac or pulmonary dysfunction. Thiotepa Fegestin Injection is not intended for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation and is to be used 48 hours after the end of the administration of chemotherapeutic drugs. The medication must be administered in strict accordance with the professional doctor’s prescription.